Pfizer, Ionis will feel the blow of COVID-19 on the fast-growing ATTR market: report

22nd April 2020 Uncategorised 0

SVBLeerink analysts had expected sales of Pfizer’s hot new drug Vyndaqel to treat ATTR cardiomyopathy to come in at $2.34 billion this year. Then COVID-19 struck, delaying diagnoses and dampening expectations—not just for Vyndaqel, but for Ionis’ rival drug Tegsedi. Can they catch up after the pandemic ends?

More: Pfizer, Ionis will feel the blow of COVID-19 on the fast-growing ATTR market: report
Source: fierce